Damora Therapeutics (DMRA) Assets Average (2020 - 2026)
Damora Therapeutics' (DMRA) quarterly Assets Average came in at $398.0 million in Q1 2026, up 2349.36% YoY from $16.2 million in Q1 2025, and up 193.43% on a QoQ basis from $135.6 million in Q4 2025.
Damora Therapeutics (DMRA) Assets Average (2020 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 7 years of Assets Average data on file, last reported at $398.0 million in Q1 2026.
- Quarterly Assets Average rose 2349.36% year-over-year to $398.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $398.0 million (up 2349.36% YoY) and the FY2025 annual result came in at $138.8 million, up 401.56% from the prior year.
- Assets Average grew to $398.0 million in Q1 2026, from $135.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $398.0 million in Q1 2026 to a low of $12.2 million in Q3 2025.
- A 5-year average of $76.4 million and a median of $54.4 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average plunged 54.11% — and 2026, when it jumped 2349.36%.
- Tracing DMRA's Assets Average over 5 years: stood at $77.6 million in 2022, then sank by 43.13% to $44.1 million in 2023, then plunged by 54.11% to $20.3 million in 2024, then surged by 569.65% to $135.6 million in 2025, then surged by 193.43% to $398.0 million in 2026.
- The last three Assets Average figures came in at $398.0 million (Q1 2026), $135.6 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 539.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 539.54 Mn |
| Mar 31, 2026 | 397.98 Mn |
| Dec 31, 2025 | 135.63 Mn |
| Sep 30, 2025 | 12.21 Mn |
| Jun 30, 2025 | 14.53 Mn |
| Mar 31, 2025 | 16.25 Mn |
| Dec 31, 2024 | 20.25 Mn |
| Sep 30, 2024 | 25.34 Mn |
| Jun 30, 2024 | 29.89 Mn |
| Mar 31, 2024 | 35.35 Mn |
| Dec 31, 2023 | 44.14 Mn |
| Sep 30, 2023 | 54.43 Mn |
| Jun 30, 2023 | 61.72 Mn |
| Mar 31, 2023 | 68.91 Mn |
| Dec 31, 2022 | 77.61 Mn |
| Sep 30, 2022 | 87.44 Mn |
| Jun 30, 2022 | 100.89 Mn |
| Mar 31, 2022 | 115.57 Mn |
| Dec 31, 2021 | 129.04 Mn |
| Sep 30, 2021 | 141.35 Mn |